Advertisement

Topics

Latest "Odonate Therapeutics" News Stories

22:38 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Odonate Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Odonate Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics for you to read. Along with our medical data and news we also list Odonate Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics Companies for you to search.

Showing "Odonate Therapeutics" News Articles 1–25 of 8,100+

Relevant

Odonate Therapeutics: Insiders Buying This Oncology Concern


Isolation on a remote island: genetic and morphological differentiation of a cosmopolitan odonate

Evolutionary history of a beautiful damselfly, Matrona basilaris, revealed by phylogeographic analyses: the first study of an odonate species in mainland China


Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly Odonate Therapeutics LLC, is a pharmaceutical company that develops medicines for the treatment of cancer. The company provides product candidate, tesetaxel which is a novel orally administered taxane used for the treatment of advanced and metastatic breast cancer. Taxanes are class of anticancer agents that destroy cancer cells by preventing them ...

Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly Odonate Therapeutics LLC, is a pharmaceutical company that develops medicines for the treatment of cancer. The company provides product candidate, tesetaxel which is a novel orally administered taxane used for the treatment of advanced and metastatic breast cancer. Taxanes are class of anticancer agents that destroy cancer cells by preventing them ...

Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly Odonate Therapeutics LLC, is a pharmaceutical company which develops medicines for the treatment of cancer. Its lead product candidate, tesetaxel, is a novel orally administered taxane used for the treatment of advanced or metastatic breast cancer. Taxanes are class of anticancer agents that destroy cancer cells by preventing them from entering mit...

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2018. As of September 30, 2018, Odonate had $161.0 million in cash, compared ...

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2018. As of June 30, 2018, Odonate had $177.4 million in cash, compared to $198...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.

Roche’s Genentech agrees to buy Jecure Therapeutics

Based in San Diego of California, Jecure Therapeutics is engaged in the discovery of therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics president and CEO The post Roche’s Genentech agrees to buy Jecure Therapeutics appeared first on Pharmaceutical Business review.

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific The post HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics appeared first on Pharma Business review.

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Probably Relevant

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Dermatology start-up Hoth Therapeutics files for IPO

Hoth Therapeutics Inc. (technology that creates a topical agent from existing therapeutics to treat skin diseases) filed for ...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

HiFiBio acquires H-Immune Therapeutics

HiFiBio Therapeutics acquired French biotech H-Immune Therapeutics, a privately held firm developing immuno-oncology therapie...

AdoRx raises $10m funding to discover new cancer therapeutics

UK-based AdoRx Therapeutics, which is focused on discovering new cancer therapeutics, has secured an initial $10m investment round financed by Epidarex Capital and CRT Pioneer Fund (CPF).

SMi Group announces the 10th Annual RNA Therapeutics Conference

20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board...    

Carisma Therapeutics to expand its technology platform towards clinical development

Carisma Therapeutics Inc., formerly CARMA Therapeutics, a privately─held biotechnology company focused on the development of macrophage─based immunotherapeutics, announced the close of a $53 million Series A

e-therapeutics, Novo Nordisk enter into research collaboration deal

Under the agreement, the two companies will use e-therapeutics’ network-driven drug discovery platform for the identification of new therapeutics approaches to treat Type 2 diabetes, which currently accounts The post e-therapeutics, Novo Nordisk enter into research collaboration deal appeared first on Pharmaceutical Business review.

Summit Therapeutics plc: Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Summit Therapeutics plc('Summit', or the 'Company')Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceOxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics p...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks